Annual Drug Patent Expirations for REYVOW
Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.
This drug has thirty-eight patent family members in thirty countries.
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
